Liberaxim

Quick links to important sections

Liberaxim

Method of action: Analgesic

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Liberaxim

Quick Facts

Property Description
Active Ingredient Hydromorphone Hydrochloride (Hydromorphone)
Form Tablets (IR/ER), Injection Solution
Pharmacological Class Opioid Analgesic
Common Use Management of Moderate-to-Severe Pain
Origin Semi-synthetic (Phenanthrene-derived)

What Type of Medicine is Liberaxim, and What is its Primary Class?

Liberaxim is a medicinal preparation whose active component is Hydromorphone Hydrochloride, and it is classified as a potent opioid analgesic. It is a semi-synthetic compound, chemically derived from the natural opium alkaloid morphine. Hydromorphone is clinically recognized for its significantly higher potency compared to morphine. This medication is reserved for the management of pain that is severe enough to require an opioid when alternative treatment options are inadequate, confirming its role in substantial pain intervention.

Composition and Available Pharmaceutical Forms

The core composition of Liberaxim is solely the active ingredient Hydromorphone Hydrochloride, classifying it as a single-entity product combined with standard pharmaceutical excipients or an aqueous base. To meet various clinical needs, Hydromorphone is provided in several dosage form(s). These forms primarily include tablets for oral administration (available as both immediate-release and extended-release formats) and a sterile injection solution intended for parenteral administration. This comprehensive range of preparations ensures that the medication delivery can be appropriately matched to the patient's pain profile, whether acute or chronic.

High-Level Purpose: Analgesia and Central Action

The primary purpose of Liberaxim is to achieve intensive analgesia, which is the relief of pain that is debilitating or resistant to milder medications. The drug exerts its effect by acting as a powerful mu-opioid receptor agonist within the central nervous system. This central action allows the substance to interrupt and significantly modulate the pain signals traveling to the brain, thereby changing the patient's perception of the pain's severity. This mechanism is crucial for complex pain states, distinguishing its function from local or peripheral acting pain relievers.

What side effects are possible with Liberaxim?

Possible Side Effects and Safety Information for Liberaxim

The safety profile of a medicinal product is officially established and communicated by government regulatory agencies through documentation that classifies and quantifies observed adverse reactions. For the proprietary name Liberaxim, no specific, official regulatory documentation regarding its safety profile is publicly available from major global health authorities such as the EMA, FDA, NIH/MedlinePlus, or others.

Without an authorized regulatory document (such as a Summary of Product Characteristics or FDA label), the drug’s definitive risk profile cannot be officially structured or detailed. The following domains represent the standard organization used by health authorities to communicate risk, but they currently contain no documented information for this specific product name:


Safety Domain Regulatory Documentation Status
Adverse Reactions by System-Organ Class (SOC) Not documented in official sources.
Frequency-Classified Adverse Reactions Not documented (e.g., Very Common, Common, Rare).
Serious Adverse Reactions (SARs) Not officially identified or listed.
Safety-Related Restrictions/Contraindications None officially defined.
Population-Specific Safety Considerations None officially defined (e.g., in pediatrics, renal/hepatic impairment).

Context of Regulatory Risk Structure

Official government documents structure a medicine's risks by grouping side effects into System-Organ Classes (e.g., disorders of the nervous system or gastrointestinal tract) to categorize where effects occur in the body. They then assign a frequency classification to these events, which provides a statistical context for their occurrence in clinical study populations. The clear designation of Serious Adverse Reactions and formal Contraindications defines the boundaries of risk and safe use. As no such regulatory data for Liberaxim has been identified, a government-defined understanding of its risks remains undefined.

Overdose and Emergency Response

A Liberaxim overdose is defined by profound depression of the central nervous system (CNS) and respiratory function, based on official regulatory labeling. Clinical manifestations documented in official prescribing information include severe somnolence progressing to stupor or coma, coupled with slowed, shallow, or difficult breathing that can lead to respiratory arrest. Additional signs include pinpoint pupils (miosis), skeletal muscle flaccidity, hypotension (low blood pressure), and bradycardia (slowed heart rate).

Overdose represents a life-threatening scenario with potential severe outcomes such as circulatory depression, shock, and cardiac arrest, which may result in brain damage or death. Furthermore, official labeling emphasizes the critical risk that accidental ingestion of even one dose by a child can result in a fatal overdose.

When to Seek Immediate Medical Help

Regulatory authorities require that a suspected overdose mandates seeking emergency medical help immediately. This applies to any observed sign of severe somnolence, inability to wake up, or slow breathing. Immediate action involves contacting emergency services and the Poison Control Helpline.

Official Overdose Management

The documented treatment relies on the administration of an opioid antagonist, such as naloxone, to reverse respiratory depression, alongside symptomatic and supportive measures. These measures include reestablishing a patent airway and providing assisted or controlled ventilation.

Therapeutic Uses of Liberaxim

What Liberaxim Treats: Main Uses and Benefits

Liberaxim (Hydromorphone) is commonly used in situations involving symptoms related to severe physical discomfort and may be part of symptomatic management that involves additional support when less potent analgesic support is insufficient. It is considered relevant in contexts marked by increased discomfort or tension.

This medication is generally applied in addressing symptoms related to heightened physiological activity that may create noticeable physiological strain, such as severe pain following major surgery (postoperative pain), episodic flares of intense discomfort (breakthrough pain), and managing the symptom burden associated with unremitting chronic pain. This medication is utilized to relieve severe pain.

“This support assists with maintaining functional stability when symptoms are more noticeable.”

This support contributes to improved comfort during periods of heightened symptoms, provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations. It is commonly used for patients requiring greater symptomatic support, and is relevant in contexts involving a heightened systemic burden and continuous management.


Quick Fact: Symptomatic Support
Primary Focus Conditions characterized by periods of heightened symptoms (Severe, Refractory, Episodic)
Core Benefit Symptomatic Relief and Assistance with Functional Stability
Typical Context Applied in clinical settings that involve acute or unstable symptom patterns

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Liberaxim (Hydromorphone) is strictly governed by governmental regulatory standards and contraindications. This section outlines the populations permitted, restricted, or prohibited from using the medicine based on official labeling.

Populations for Whom Use is Prohibited

Classification Population/Condition
Contraindicated Patients with significant respiratory depression or acute/severe bronchial asthma.
Contraindicated Patients with known or suspected gastrointestinal obstruction, such as paralytic ileus.
Contraindicated Patients with known hypersensitivity to hydromorphone or any component of the formulation.
Contraindicated Opioid Non-Tolerant Patients (specifically for extended-release and high-potency formulations).

Age and Physiological Status Eligibility

Status Official Regulatory Stance
Pediatric Use Safety and effectiveness are not established in pediatric patients.
Geriatric Use Use requires caution and monitoring due to increased sensitivity and likely decreased organ function.
Pregnancy Not recommended for prolonged use due to the risk of Neonatal Opioid Withdrawal Syndrome.
Lactation Not recommended; hydromorphone is excreted in breast milk with potential risk to the infant.

Condition-Specific Eligibility Limitations

Use requires special consideration and/or a reduced initial starting dose for patients with hepatic impairment (liver disease) or renal impairment (kidney disease). Caution is also mandated for patients with pre-existing conditions that affect respiratory reserve, such as COPD, and for those with head injury or increased intracranial pressure.

What should I know about interactions with other medicines?

Liberaxim (Hydromorphone) interacts with several medicinal products and substances, primarily through pharmacodynamic reinforcement and specific pharmacokinetic modifications. Co-administration with Central Nervous System ( CNS) depressants (including benzodiazepines, sedative-hypnotics, and alcohol) is officially documented to cause additive effects, which can result in profound sedation, life-threatening respiratory depression, and coma. Due to this risk, the co-administration of such agents is strictly regulated.

The regulatory labels also note several restricted combinations. Monoamine Oxidase Inhibitors ( MAOIs) are cautioned against, requiring a mandatory separation of at least 14 days after discontinuation before Liberaxim can be initiated. Other high-risk combinations include Serotonergic drugs, which can lead to the serious condition of Serotonin Syndrome, and Mixed Agonist/Antagonist Opioids, which may precipitate withdrawal symptoms or reduce analgesic efficacy. Concomitant use with Anticholinergic agents also increases the risk of urinary retention and paralytic ileus.

Official documentation details how the drug's exposure is affected by patient health status. In individuals with moderate hepatic impairment, Liberaxim exposure (plasma levels) is documented to increase by approximately 4-fold. Patients with renal impairment also exhibit altered clearance, resulting in a 2- to 3-fold increase in exposure, a factor that alters the overall interaction profile in these populations.

Mechanism of Action

How Liberaxim Works

Liberaxim's action is defined by a highly targeted pharmacodynamic mechanism, centered entirely on the modulation of central opioid signaling, resulting in specific alterations in physiological function.


Targeted Agonism of Central Opioid Receptors

This domain covers the primary biological targets and the initial molecular interaction. The drug acts as a full agonist predominantly on the mu-opioid receptor (MOR) in the spinal cord and brain, initiating an inhibitory signal at the cellular level by coupling with Gi/o-proteins. This mechanism immediately begins to reduce the excitability of the key neurons of the nociceptive signaling pathways, resulting in the modulation of afferent nociceptive transmission.


Modulation of Inhibitory Gi/o-Protein Cascades

This domain addresses the downstream molecular sequence and resulting system-wide effects. The MOR activation triggers a cascade that lowers intracellular cAMP and modulates ion channels (potassium efflux, calcium influx inhibition), leading to neuronal hyperpolarization and a reduction in the release of excitatory neurotransmitters. This inhibitory process extends beyond nociceptive pathways to the medullary respiratory center and gastrointestinal smooth muscle, resulting in decreased activity of the respiratory drive and reduced gastrointestinal motility.


Mechanistic Constraints and Pathway Adaptation

This domain explains the intrinsic limitations associated with prolonged receptor agonism. Continuous MOR stimulation initiates compensatory feedback mechanisms, including receptor desensitization and internalization, which reduces the number of functional receptors on the cell surface. These adaptive cellular changes are the underlying mechanistic reason for the development of tolerance and mechanistically underlie the phenomenon of opioid-induced hyperalgesia (OIH).

Dosage and Administration Information

Liberaxim's usage protocol is determined by its formulation. The medication is administered via oral (tablets and solution) and parenteral (Intravenous, Subcutaneous, or Intramuscular) routes. The choice between an Immediate-Release (IR) form and an Extended-Release (ER) tablet dictates the dosing schedule. IR forms are typically administered every 4 to 6 hours for managing severe pain episodes. Conversely, the ER tablet is administered once daily for continuous, around-the-clock pain management.

For opioid-naïve adult patients, the initial oral IR dose is typically 2 mg to 4 mg, while the parenteral IV starting dose ranges from 0.2 mg to 1 mg. Subsequent maintenance dosing is achieved through individual titration guided by a structured schedule. Oral formulations may be taken with or without food.

A critical instruction for the Extended-Release tablet is that it must be swallowed whole and never crushed, chewed, or dissolved, as this would compromise the controlled-release mechanism. Furthermore, special consideration is required for patients with hepatic or renal impairment, which involves initiation with a dose reduction of up to 50% of the usual starting dose. When discontinuing the medication, the daily dose is gradually tapered to prevent withdrawal effects.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Phase I Studies: Pharmacodynamics and Safety

Phase I research evaluated the drug's safety profile and how the body handles the compound (pharmacokinetics). Studies in healthy volunteers established initial tolerability across various dose ranges.

Preclinical research investigated the compound's behavior in relation to central nervous system (CNS) pathways. Research examined whether the drug's activity related to pain signals in individuals with neuropathic conditions.


Efficacy Data from Phase II and III Trials

Key Phase III trials evaluated the effect on the quality of life for individuals with Post-Herpetic Neuralgia (PHN). These studies used standard pain scales to record outcomes.

  • Trial participants receiving the drug reported changes in pain scores over the study period, suggesting its use warrants further study.
  • The primary endpoint of a reduction in daily pain score was achieved in some study arms. The findings were mixed across different patient cohorts in terms of magnitude and duration of effect, as reported by the investigators.
  • Long-term follow-up examined the continued reporting of changes in pain scores over a 52-week period.

Investigated Combination Therapies

One observational study explored whether co-administration of drug X with physical therapy correlated with changes in mobility and long-term outcomes, examining a potential synergistic effect. The study did not report sufficient evidence to support definitive conclusions.

Safety and Adverse Events Profile

Adverse event reporting in clinical trials was dominated by events categorized as mild to moderate in severity. These commonly included dizziness, somnolence, and peripheral edema.

  • Data indicates a profile of reported side effects, and some studies suggest the need to monitor liver function in trial participants. These potential events were documented as rare in the study population.
  • Trial protocols described the study drug being reduced slowly to manage the potential for withdrawal symptoms.

A head-to-head trial compared the tolerability and efficacy profile of the drug to another studied intervention for chronic neuropathic pain.

Key Studies & References

  1. Efficacy and safety of different medications compared for the treatment of postherpetic neuralgia: a network meta-analysis
  2. Study Details | NCT03681613 | Exercise Therapy in Combination With Central Nervous System-targeted Treatment for Osteoarthritis [Source for combination therapy concept, used neutrally]

Frequently Asked Questions (FAQ)

Common questions about Liberaxim (FAQ)

Q: What happens if I stop using Liberaxim suddenly?

A: Regulatory documents state that in patients who have developed physical dependence, abruptly stopping the medication has led to the development of serious withdrawal symptoms. These effects can include severe pain and significant emotional distress. Regulatory information indicates that discontinuation should be achieved through a gradual dose tapering process to manage withdrawal.

Q: Do any common foods or drinks interfere with Liberaxim?

A: Official product information indicates that this medication may be taken either with or without food. However, it is explicitly noted that using this medicine at the same time as alcohol can lead to serious risks, including profound sedation, breathing difficulties, and coma.

Q: Is Liberaxim considered a high-risk medication?

A: Yes, this medication is classified by regulatory authorities as a Schedule II controlled substance. This classification reflects its high potential for abuse, addiction, and misuse. Due to these risks, the drug is managed under strict protocols, such as a Risk Evaluation and Mitigation Strategy (REMS).

Q: What is the most commonly reported side effect of Liberaxim?

A: Studies indicate that the most common adverse reactions reported by patients during clinical trials include nausea, vomiting, and constipation. Other frequently reported effects are general drowsiness (somnolence), headaches, and dizziness.

Q: Are the side effects from Liberaxim generally mild?

A: Side effects range in severity. While many commonly reported reactions like nausea and dizziness are mild, official information also describes the risk of serious and life-threatening events. The most serious concern is severe respiratory depression (slowed breathing), particularly when the medication is combined with other central nervous system depressants.

Q: Why do some people say Liberaxim gave them stomach issues?

A: Like other medicines in its class, this drug can cause stomach and gastrointestinal issues, most commonly constipation. This is due to the drug's action of reducing gastrointestinal motility. In rare cases, the medication may lead to a severe bowel problem called paralytic ileus (a form of obstruction).

Q: Does Liberaxim interact with supplements like vitamins or herbal products?

A: Official information specifically notes potential interactions with the herbal supplement St. John's wort and the essential amino acid tryptophan. It is important that a healthcare professional is aware of all nonprescription or herbal products used.

Q: How does the mechanism of Liberaxim differ from older treatments for the same condition?

A: This drug belongs to the class of opioid analgesics and works by changing how the brain and nervous system process pain signals. Studies have shown that the active ingredient is significantly more potent than morphine, which is one of the older, naturally derived opioids used for pain management.

Q: Can taking Liberaxim affect my ability to drive?

A: Official information states this medication may impair the mental and physical abilities required for hazardous tasks. Because of side effects like dizziness and drowsiness (somnolence), patients are cautioned against driving or operating heavy machinery.

Q: Is Liberaxim a habit-forming drug?

A: Regulatory documents classify this as a Schedule II controlled substance due to its high potential for abuse and physical dependence. This indicates that the medication may be habit-forming, and patients can develop tolerance to its effects over time.

Q: What are the signs of a severe allergic reaction to Liberaxim mentioned in official documents?

A: Although rare, the medication has been associated with reports of severe allergic reactions, including anaphylaxis. Signs of such a reaction include difficulty breathing, swelling of the face, tongue, or throat, or a spreading rash or hives.

Q: Does Liberaxim have a generic version available?

A: The active ingredient in this medicine, hydromorphone hydrochloride, is widely available in generic formulations. These generic versions are approved by regulatory bodies, such as the FDA, as chemically equivalent to the proprietary product.

Q: What kind of patient monitoring is generally needed while using Liberaxim?

A: Official prescribing information mandates monitoring for signs of addiction, abuse, and misuse. Additionally, patients are monitored for significant side effects like respiratory depression (slowed breathing) and extreme drowsiness (sedation).

Q: Are there reports of Liberaxim causing skin rashes?

A: Yes, skin reactions have been reported, including generalized rash and pruritus (itching). For the injectable form, reports of hives or rash at the injection site have also been noted in official documents.

Q: What medical conditions is Liberaxim not approved to treat?

A: Regulatory documents state that this medication is only indicated for the management of severe pain that requires an opioid and where alternative treatments have been insufficient. It is not intended for the management of pain that can be adequately controlled with non-opioid pain relievers.

Q: Are patients who use Liberaxim usually advised to avoid any specific activities?

A: Due to the potential for the medication to cause sedation, dizziness, and impairment, official labeling advises against driving a car or operating heavy machinery. This guidance is applicable until a patient understands how the drug specifically affects their ability to perform these tasks.

Q: Why is Liberaxim only available by prescription?

A: This medication is restricted to prescription use because regulatory bodies classify it as a Schedule II controlled substance. This classification is based on its high potential for abuse and dependence. Its distribution is subject to strict governmental controls and monitoring.

Q: How quickly should I expect Liberaxim to start working?

A: According to pharmacokinetics data, the immediate-release oral formulations typically begin to take effect within 15 to 30 minutes after use. For the extended-release formulations, the onset of action is significantly longer, often around six hours.

Q: How long does Liberaxim typically stay in your system?

A: Pharmacokinetics data describes how long the drug stays in the body using its half-life. The half-life for the immediate-release form is typically between 2 and 3 hours, while the extended-release form has a significantly longer half-life, reported to be around 11 hours.

Q: Is it safe to use Liberaxim if I have high blood pressure?

A: Official information indicates that changes in blood pressure, including both high blood pressure (hypertension) and low blood pressure (hypotension), have been reported as adverse reactions. Monitoring of blood pressure is indicated for patients taking medications that affect blood pressure or who have existing conditions.

Q: Is Liberaxim used to treat anxiety or depression?

A: The approved use for this medication is strictly for the management of severe pain. However, official reports of adverse reactions have included psychiatric symptoms such as anxiety and depression.

Q: Is it normal to feel a bit nauseous when starting Liberaxim?

A: Yes, studies indicate that nausea is one of the most common adverse reactions reported when using this medication. It is listed among the side effects with the highest incidence in clinical trials.

Q: Is Liberaxim known to cause headaches?

A: Yes, regulatory documents list headache as one of the most common adverse reactions. It was reported with a high incidence during clinical trials of the medication.

Q: What is the common age range of people who use Liberaxim?

A: The safety and effectiveness of this medication have not been established in pediatric patients. For older adults, caution and careful initial dosing are recommended due to likely decreased organ function and increased sensitivity.

Q: How is Liberaxim usually eliminated from the body?

A: The drug is primarily processed and transformed in the liver (a process called conjugation). Once transformed, it is then eliminated from the body by renal excretion (via the kidneys).

Q: Is there a link between Liberaxim and changes in mood?

A: Yes, the medication has been associated with changes in mood, and official adverse reaction lists include both feelings of intense well-being (euphoria) and feelings of unease or dissatisfaction (dysphoria). Reports also list psychiatric disorders such as anxiety, depression, and agitation.

Q: Does Liberaxim interfere with lab test results?

A: While regulatory documents do not list specific interferences with common lab tests, clinical studies have noted the importance of monitoring for potential effects on hepatic enzymes (liver enzymes). Additionally, opioid analgesics can sometimes have an effect on the endocrine system.

Q: What happens if I accidentally take a higher amount of Liberaxim than directed?

A: Taking more than the prescribed amount can lead to signs of an overdose, which include severe and slowed breathing, extreme drowsiness, and loss of consciousness. Other potential effects include a slow heartbeat and low blood pressure.

How should Liberaxim be stored and disposed of?

Official Storage and Disposal Profile

All medicines must be stored and disposed of according to the specific instructions provided on the official product labeling. If specific instructions for Liberaxim are unavailable, general regulatory guidelines must be followed to ensure patient safety and environmental protection.

Mandatory Storage Requirements

  • Child Safety: Always keep the medicine and its packaging out of the sight and reach of children and pets.
  • Container: Keep the medicine in its original container until the time of disposal.
  • Stability: Store the medicine within the temperature, light, and moisture constraints noted on the label to maintain product quality.

Official Disposal Instructions

The primary method for disposal is using an authorized drug take-back program. If a take-back option is unavailable, the medicine must be prepared for disposal in the household trash. This involves removing the drug from its container, mixing it with an undesirable substance (such as dirt or coffee grounds), sealing it in a plastic bag, and then discarding it in the trash. Personal information must be completely removed or obscured from the prescription label prior to disposal. Flushing a medicine is only authorized if it is listed on the FDA's specific list of highly toxic drugs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Liberaxim found in:

A-Z Index: